Tigermed

Major Chinese CROs and consulting groups (like Tigermed) specialize in bridging the gap between China's National Medical Products Administration (NMPA) and the US FDA for cross-border drug development.

Country
China
Ticker
SZSE:300347
Commercial NMPA Focus
Coverage
CNEUINUS
market-access-commercial✓✓✓✓
regulatory-legal✓✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
Headcount11,984 global employees as of June 30, 2026prnewswire.com · tigermedgrp.com
RevenueRMB 3,707.6 million for the first half of 2026prnewswire.com
Production site25 laboratory facilities across China, the U.S., and Europe, and a 4,300 sqm CDMO GMP manufacturing facility in Exton, U.S. as of June 30, 2026tigermedgrp.com · prnewswire.com
Capacity6 co-established clinical sites with a total of 620 research beds as of June 30, 2026prnewswire.com · tigermedgrp.com
CertificationTaya AI platform obtained ISO 20000 and ISO 27001 certifications; laboratories passed CAP accreditationtigermedgrp.com
Regulatory approvalAssisted in 49 Class I new drug and 5 innovative medical device approvals in China in 2025tigermedgrp.com
PartnershipStrategic cooperation agreements with Hisun Pharmaceutical, Insilico Medicine, 3SBio, and a leading European multinational pharmaceutical company in H1 2026prnewswire.com

Independent sources: prnewswire.com

Technologies
NameClusterRisk
CMC regulatory consulting (BLA/MAA)regulatory-legalLow→
Multi-jurisdictional bio-compliance (FDA+EMA+NMPA+PMDA)market-access-commercialLow→
Named-patient programs & compassionate usemarket-access-commercialLow→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.